Nanexa's Stock Surges Amidst €1.17 Billion Novo Nordisk Deal
Nanexa's shares soared over 120% following a landmark deal with pharmaceutical giant Novo Nordisk. The €1.17 billion agreement grants Novo exclusive rights to Nanexa's PharmaShell technology for developing injectable drugs. This strategic move aims to revolutionise diabetes and obesity treatments, …
Read more →
